Be Cautious, SNPX. 换汤不换药

Synaptogenix, Inc  (OTC: SNPX), renamed from Neurotrope Bioscience, Inc., which failed in previous Phase II clinical trial of its main drug, Bryostatin-1 for Alzheimer's disease.

Bryostatin-1 is still main drug of Synaptogenix Inc, which I can not see any hope.

 

 

所有跟帖： 

• 谢谢提醒 -挨踢- ♂ (0 bytes) () 03/29/2021 postreply 19:38:07

• 才看到，我解释一下，NTRP 的前面几期trial数据不差的，有错误有发现，科学试验不就是从一步一步的失败中成功的么。我其实也不 -beyondbetween- ♀ (3869 bytes) () 03/30/2021 postreply 13:26:46